• Main Publications
• Ongoing Research Projects
• Group’s Recognitions
• Theses

​

Main Publications

• Forcano L, Mata F, de la Torre R, Verdejo-García A. Cognitive and Neuromodulation Strategies for Unhealthy Eating and Obesity: Systematic Review and Discussion of Neurocognitive Mechanisms. Neurosci Biobehav Rev 2018; 87: 161-191. IF 8.037. D1.

• Antón M, Rodríguez-González A, Rodríguez-Rojo IC, Pastor A, Correas Á, Serrano A, Ballesta A, Alén F, Gómez de Heras R, de la Torre R, Rodríguez de Fonseca F, Orio L. Increased plasma oleoylethanolamide and palmitoleoylethanolamide levels correlate with inflammatory changes in alcohol binge drinkers: the case of HMGB1 in women. Addict Biol 2018; 23(6): 1242-1250. IF 5.578. Q1.

• Galindo L, Moreno E, López F, Guinart D, Cuenca A, Izquierdo-Serra M, Xicota L, Fernández-Avilés C, Menoyo E, Fernández-Fernández JM, Benítez-King G, Canela EI, Casadó V, Pérez V, de la Torre R, Robledo P. Cannabis Users Show Enhanced Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium Cells. Mol Neurobiol 2018; 55(8): 6347-6361. IF 5.076. Q1.

• Rodríguez-Morató J, Matthan NR, Liu J, de la Torre R, Chen CO. Cranberries attenuate animal-based diet-induced changes in microbiota composition and functionality: a randomized crossover controlled feeding trial. J Nutr Biochem 2018; 62: 76-86. IF 4.414. Q1.

• Berrendero F, Flores Á, Robledo P. When Orexins Meet Cannabinoids: Bidirectional Functional Interactions. Biochem Pharmacol 2018; 157: 43-50. IF 4.235. Q1.

• Faundez V, De Toma I, Bardoni B, Bartesaghi R, Nizetic D, de la Torre R, Cohen Kadosh, Herault Y, Dierssen M, Potier MC, Down Syndrome and Other Genetic Developmental Disorders ECNP Network. Translating molecular advances in Down syndrome and Fragile X syndrome into therapies. Eur Neuropsychopharmacol 2018; 28(6): 675-690. IF 4.129. Q1.

• Portero-Tresserra M, Gracia-Rubio I, Cantacorps L, Pozo O, Gómez-Gómez A, Pastor A, López-Arnau R, de la Torre R, Valverde O. Maternal separation increases alcohol-drinking behaviour and reduces endocannabinoid levels in the mouse striatum and prefrontal cortex. Eur Neuropsychopharmacol 2018; 28(4): 499-512. IF 4.129. Q1.

• Kuypers KPC, de la Torre R, Farré M, Xicota L, de Sousa Fernandes Perna EB, Theunissen EL, Ramaekers JG. Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter. Sci Rep 2018; 8(1): 1061. IF 4.122. Q1.

• Mallorquí-Bagué N, Lozano-Madrid M, Toledo E, Corella D, Salas-Salvadó J, Cuenca A, Vioque J, Romaguera D, Martínez JA, Warnberg J, et al. Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study. Sci Rep 2018; 8(1): 16128. IF 4.122. Q1.

• Papaseit E, Farré M, Pérez-Mañá C, Torrens M, Ventura-Vilamala M, Pujadas-Bastardes M, de la Torre R, González D. Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. Front Pharmacol 2018; 9: 206. IF 3.831. Q1.

​

​

Ongoing Research Projects

• Salut Mental, Nutrició i Cognició: Estudi de seguiment de l'Impacte d'una Intervenció en Dieta Mediterrània i Promoció de l'Activitat Física en Gent Gran amb Sobrepès i Obesitat

- Financing institution: Departament de Salut. Generalitat de Catalunya (SLT006/17/00246)

- Period: from 2018 to 2020

- Principal investigator: De la Torre Fornell, Rafael

• Prevención del deterioro cognitivo en personas con Quejas Subjetivas de Memoria o Deterioro Cognitivo Leve tras una intervención con Dieta Mediterránea

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI17/00223)

- Period: from 2018 to 2020

- Principal investigator: De la Torre Fornell, Rafael

• Formación de Hidroxitirosol e ingesta de cerveza: implicaciones para la salud

- Financing institution: Centro de Información Cerveza y Salud (CICS)

- Period: from 2018 to 2019

- Principal investigator: Soldevila Domènech, Natàlia

• Novel Biomarkers in Recombinant Human Growth Hormone Abuse Detection, LC-MRM-MS method for Fibronectin Quantification in Anti-Doping Routine

- Financing institution: World Anti-Doping Agency (17A07GR)

- Period: 2018

- Principal investigator: Reverter Branchat, Gemma

• Development of new fatty acid conjugates for the treatment of the non-alcoholic steatohepatitis (NASH)

- Financing institution: BIOCAT

- Period: 2018

- Principal investigator: De la Torre Fornell, Rafael

• Screening Emerging Stimulants by Analytical and Metabolic Evaluations

- Financing institution: Partnership for Clean Competition (PCC)-USADA

- Period: 2018

- Principal investigator: Pozo Mendoza, Óscar

• Caracterització dels determinants genètics dels fenotips de neuroimatge associats a la malaltia d’Alzheimer en participants de la cohort ALFA

- Financing institution: Departament de Salut. Generalitat de Catalunya (SLT002/16/00201)

- Period: from 2017 to 2019

- Principal investigator: De la Torre Fornell, Rafael

• Desarrollo de nuevos conjugados de ácidos grasos para el tratamiento de las esteatohepatitis

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (DTS16/00035)

- Period: from 2017 to 2019

- Principal investigator: De la Torre Fornell, Rafael

• Role of serotonin in the rescuing effects of cognitive therapies: in vivo study of neural network dynamics in mouse models of Down syndrome and schizophrenia

- Financing institution: Ministerio de Economía y Competividad (SAF2016-80726-R)

- Period: from 2016 to 2019

- Principal investigator: Puig Velasco, María Victoria

• Medida de biomarcadores específicos del uso de cigarrillos electrónicos (propilenglicol) y tabaco (nicotina, carcinógenos) en una cohorte de usuarios de cigarrillos electrónicos

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI15/00434)

- Period: from 2016 to 2019

- Principal investigator: Pascual Esteban, José Antonio

• Evaluation of dose and source of green tea extracts as contributing factors to treatment efficacy and hepatotoxicity. Therapeutic implications in Down syndrome

- Financing institution: Fondation Jérôme Lejeune (1493)

- Period: from 2016 to 2019

- Principal investigator: Pizarro Lozano, Nieves

• Neural activity patterns of cognitive normalization mediated by environmental enrichment and epigallocatechin-3-gallate in a murine model of Down syndrome

- Financing institution: Fondation Jérôme Lejeune

- Period: from 2016 to 2018

- Principal investigator: Puig Velasco, María Victoria

• Ultra-sensitive mass spectrometric detection of a rEPO specific O-glycopeptide as an unambiguous proof of doping-Follow up (GOpep2)

- Financing institution: World Anti-Doping Agency (15A31JP)

- Period: from 2016 to 2018

- Principal investigator: Pascual Esteban, José Antonio

• BIs-Conjugates in the Endogenous Profile of Steroids (BICEPS)

- Financing institution: World Anti-Doping Agency (15A29OP)

- Period: from 2016 to 2018

- Principal investigator: Pozo Mendoza, Óscar

• Immunorecognition of specific markers of blood storage. Customization and testing of already developed antibodies

- Financing institution: World Anti-doping Agency (ISF16M04JP)

- Period: from 2016 to 2018

- Principal investigator: Pascual Esteban, José Antonio

• Remodelando el desarrollo cerebral: potenciación de la plasticidad neuronal para mejorar el rendimiento cognitivo en síndromes que causan discapacidad intelectual

- Financing institution: Fundación Mutua Madrileña (AP157312015)

- Period: from 2015 to 2019

- Principal investigator: De la Torre Fornell, Rafael

• Neural Substrates of Atypical Antipsychotic Drug Action: Role of Serotonin 5-HT1A and 5-HT2A Receptors in Neural Network Dynamics in the Mouse Prefrontal Cortex and Hippocampus during Executive Function

- Financing institution: Brain & Behavior Research Foundation (23014)

- Period: from 2015 to 2018

- Principal investigator: Puig Velasco, María Victoria

• Characterization of novel suppressors of neurodegeneration in myotonic dystrophy type 1 (DM1)

- Financing institution: Fundació La Marató de TV3 (20143530)

- Period: from 2015 to 2018

- Principal investigator: Robledo Montoya, Patricia

• El consumo moderado de vino promueve la generación endógena del antioxidante natural hidroxitirosol. Implicaciones en la prevención de enfermedades cardiovasculares

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI14/00072)

- Period: from 2015 to 2018

- Principal investigator: De la Torre Fornell, Rafael

• Implicación de los heterómeros CB1-5-HT2A en las alteraciones cognitivas y conductuales de la esquizofrenia y su interacción con el consumo de cannabis: un enfoque traslacional

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI14/00210)

- Period: from 2015 to 2018

- Principal investigator: Robledo Montoya, Patricia

• Estudio metabolómico en pacientes con Porfiria Aguda Intermitente: caracterización de los desajustes hormonales y catabólicos asociados a la enfermedad y efectos del tratamiento con hemina

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI14/00147)

- Period: from 2015 to 2018

- Principal investigator: Pozo Mendoza, Óscar

• Proyecto Ramón y Cajal

- Financing institution: Ministerio de Economía y Competitividad (RYC-2012-10042)

- Period: from 2014 to 2018

- Principal investigator: Puig Velasco, María Victoria

 

​

Group’s Recognitions

• Officially recognized as a consolidated research group by the Generalitat de Catalunya: Grup de Recerca Clínica en Farmacologia i Desenvolupament de Biomarcadors i Nous Fàrmacs (2017-2020)

- Agència de Gestió d’Ajuts Universitaris i de Recerca (SGR 138)

- Principal investigator: De la Torre Fornell, Rafael

• Officially recognized as an emergent research group by the Generalitat de Catalunya: Grup de recerca en neuroquímica i neurofisiologia de la cognició en malalties psiquiàtriques i del desenvolupament (2017-2020)

- Agència de Gestió d’Ajuts Universitaris i de Recerca (SGR 210)

- Principal investigator: Puig Velasco, María Victoria

 

​

Theses

• Kossatz de Mello E. Neuroprotective mechanisms of CB2 cannabinoid receptors and PPAR-α in hypoxia/ischemia-induced brain damage. Universitat Pompeu Fabra.

- Directors: Robledo Montoya, Patricia; Maldonado López, Rafael

- Date of defense: 08/06/2018

• Olesti E. Approaches to evaluate the pharmacology of new psychoactive substances. Universitat Pompeu Fabra.

- Directors: De la Torre Fornell, Rafael; Pozo Mendoza, Óscar

- Date of defense: 29/11/2018

 

​